-
公开(公告)号:KR100424392B1
公开(公告)日:2004-03-24
申请号:KR1020010041239
申请日:2001-07-10
Applicant: 한국화학연구원
IPC: A61K31/165
Abstract: PURPOSE: A pharmaceutical composition containing myxochelin-A which exhibits excellent anticancer activity against human cancer cells, together with excellent antioxidant activity as a main component is provided which can be effectively used as an effective antioxidant and anticancer agent. CONSTITUTION: The pharmaceutical composition contains myxochelin-A of formula 1 obtained by being separated from myxobacteria or being chemically synthesized or semisynthesized. The myxochelin-A is purely separated by the steps of: separating a biomass and absorption resin by culturing Angiococcus disciformis strains as myxobacteria in the presence of absorption resin and centrifuging a culture solution; adding an organic solvent, preferably a mixed solvent of acetone and methanol; extracting and filtering to remove the biomass and absorption resin; preparing an active fraction by concentrating the filtrate under reduced pressure and extracting a crude extract in an organic solvent; and successively performing silica gel liquid chromatography and recycling preparative HPLC.
Abstract translation: 目的:提供一种药物组合物,其含有对人癌细胞具有优异的抗癌活性以及优异的抗氧化活性作为主要组分的粘液溶血素A,其可以有效地用作有效的抗氧化剂和抗癌剂。 组成:药物组合物含有通过从粘细菌分离或化学合成或半合成获得的式1的粘多糖蛋白-A。 通过在吸附树脂存在下离心培养溶液培养作为粘细菌的粘细菌属细菌菌株来分离生物质和吸附树脂,纯粹分离粘液粘连素-A; 加入有机溶剂,优选丙酮和甲醇的混合溶剂; 提取并过滤去除生物质和吸收树脂; 通过在减压下浓缩滤液并在有机溶剂中萃取粗提取物来制备活性部分; 并连续进行硅胶液相色谱和再循环制备型HPLC。
-
公开(公告)号:KR1020030005787A
公开(公告)日:2003-01-23
申请号:KR1020010041239
申请日:2001-07-10
Applicant: 한국화학연구원
IPC: A61K31/165
Abstract: PURPOSE: A pharmaceutical composition containing myxochelin-A which exhibits excellent anticancer activity against human cancer cells, together with excellent antioxidant activity as a main component is provided which can be effectively used as an effective antioxidant and anticancer agent. CONSTITUTION: The pharmaceutical composition contains myxochelin-A of formula 1 obtained by being separated from myxobacteria or being chemically synthesized or semisynthesized. The myxochelin-A is purely separated by the steps of: separating a biomass and absorption resin by culturing Angiococcus disciformis strains as myxobacteria in the presence of absorption resin and centrifuging a culture solution; adding an organic solvent, preferably a mixed solvent of acetone and methanol; extracting and filtering to remove the biomass and absorption resin; preparing an active fraction by concentrating the filtrate under reduced pressure and extracting a crude extract in an organic solvent; and successively performing silica gel liquid chromatography and recycling preparative HPLC.
Abstract translation: 目的:提供能够有效地用作有效的抗氧化剂和抗癌剂的含有对人类癌细胞具有优异抗癌活性的粘液素-A的药物组合物,以及优异的抗氧化活性为主要成分。 构成:药物组合物含有通过与粘液细菌分离或化学合成或半合成获得的式1的粘液素-A。 通过以下步骤纯化粘液素-A:通过在吸收树脂存在下培养球状球形细菌菌株作为粘液细菌分离生物质和吸收树脂并离心培养液; 加入有机溶剂,优选丙酮和甲醇的混合溶剂; 提取和过滤除去生物质和吸收树脂; 通过减压浓缩滤液并在有机溶剂中萃取粗提取物制备活性级分; 并依次进行硅胶液相色谱和再循环制备型HPLC。
-